Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue

Theoharis C. Theoharides1,2,3,4,5 | Christos Cholevas5 | Konstantinos Polyzoidis5 | Antonios Politis6

1Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, Massachusetts
2School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts
3Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts
4Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts
5BrainGate, Thessaloniki, Greece
6First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University, Athens, Greece

Abstract
COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin.

KEYWORDS
brain fog, chemotherapy, coronavirus, COVID-19, cytokines, fatigue, inflammation, mast cells, microglia

1 | INTRODUCTION

Infection with the recent coronavirus (severe acute respiratory syndrome [SARS]-CoV-2) leads to COVID-19, the severity of which derives from the host’s inflammatory response that involves release of a storm of pro-inflammatory cytokines, especially interleukin-6 (IL-6), but also IL-1.

Even though symptoms associated with SARS-CoV-2 infection in children are mild, a number of recent publications reported a multisystem inflammatory syndrome (MIA-C) in older children and adolescents, often presenting with symptoms reminiscent of Kawasaki disease. Symptoms in MIA-C typically occur 4–6 weeks after infection and the disease is characterized by elevated markers of inflammation and the presence of multiple autoantibodies. A similar disease in adults,
named multisystem inflammatory syndrome (MIA-A) has been recognized by the Center for Disease Control (CDC, USA) (https://www.cdc.gov/mis-c/). In fact, autoimmune and inflammatory diseases are now increasingly identified following COVID-19. The etiology of MIA remains unknown.

Cytokine storms have also been implicated in a variety of “mystery” diseases. One such disease affects COVID-19 survivors and is associated with severe fatigue and neuropsychiatric symptoms (https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101521173), especially impairment in cognitive functions known as “brain fog” (https://www.nytimes.com/2020/10/11/health/covid-survivors.html). Such patients have been called “long-haulers” (https://directorsblog.nih.gov/tag/post-covid-syndrome/) and the illness has been termed “long-COVID syndrome” (https://directorsblog.nih.gov/2021/01/19/trying-to-make-sense-of-long-covid-syndrome/). In fact, the National Institutes of Health (NIH, USA) recently devoted a 2-day conference on the epidemiology and pathophysiology of this illness (https://www.niaid.nih.gov/news-events/workshop-post-acute-sequelae-covid-19). Other names used for this illness include “chronic COVID syndrome,” “post-COVID syndrome,” or “long haulers COVID syndrome.”

In addition to the severe respiratory and inflammatory problems discussed above, infection with SARS-CoV-2 can also contribute to neurological disorders. For this reason, NIH held an 1-day workshop on the effect of COVID-19 on the central nervous system (CNS) (https://www.ncbi.nlm.nih.gov/search/research-news/11277/) and recently launched a database to track neurological symptoms associated with COVID-19 (https://www.nih.gov/news-events/news-releases/nih-launches-database-track-neurological-symptoms-associated-covid-19). The importance of the effects of COVID-19 on the brain is highlighted by the blog recently posted by the NIH Director on this subject (https://directorsblog.nih.gov/2021/01/14/taking-a-closer-look-at-the-effects-of-covid-19-on-the-brain/).

However, few scientific publication has so far discussed long-COVID syndrome (https://www.nytimes.com/2021/01/21/magazine/covid-aftereffects.html) such as the one that reported the presence of persistent fatigue apparently independent of the severity of the initial symptoms. Symptoms experienced by long-COVID syndrome patients (Table 1) are very similar to those present in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), or systemic mastocytosis (SM) in whom the unique tissue immune cells, mast cells, are stimulated by environmental, pathogenic, and stress stimuli. Moreover, IL-6 has not only been implicated in COVID-19 but was also elevated in ME/CFS and SM. To make matters worse, IL-6 promotes an increase in number of mast cells.

### Table 1: Symptoms present in long-COVID syndrome

- Angioedema
- Brain fog
- Confusion
- Difficulty multitasking
- Dizziness
- Dysautonomia
- Fatigue
- Gastrointestinal complaints
- Headache
- Hypotension
- Insomnia
- Irritability
- Lightheadedness (syncope)
- Inability to find the right words
- Memory loss
- Myalgias
- Palpitations
- Shortness of breath
- Weakness

Note: The symptoms listed, especially those bolded, are experienced by many long-COVID syndrome patients and also patients undergoing or after having been administered chemotherapy.

## 2 | CHEMOTHERAPY

Patients undergoing chemotherapy are susceptible to infection with COVID-19.

Moreover, more than 50% of patients on or following chemotherapy develop symptoms similar to those described above for long-COVID syndrome (Table 1), especially cognitive dysfunction, a condition that has been termed “chemofog” or “chemobrain,” and has been associated with distinct neuroimaging findings. A number of drugs have been implicated in “chemobrain” (Table 2) most notably doxorubicin, methotrexate, lenalidomide, rituximab, and trastuzumab.

There have been intense efforts to understand the biochemical or cellular mechanisms responsible for chemobrain. These have included disrupted neurogenesis, aberrant myelination, interference with prefrontal activity, but most importantly neuroinflammation with cytokine dysregulation.
3 | INFLAMMATION OF THE BRAIN

Microglia have important functions in the CNS, especially with respect to neuroinflammation and neurodegenerative diseases. Microglia express Toll-like receptors (TLRs), activated by damage-associated molecular patterns (DAMPs) and were recently implicated in COVID-19. COVID-19 can also affect the hypothalamic-pituitary-adrenal (HPA) axis, which is typically activated by stress and can further affect the emotional state of individuals affected by COVID-19. Microglia also express receptors for corticotropin-releasing hormone (CRH) and could be further activated by stress, especially associated with COVID-19.

Microglia interact with the unique immune cells, mast cells, in the brain leading to their activation and neuroinflammation. Activation of mast cells and microglia in the hypothalamus could lead to cognitive dysfunction commonly also seen in patients with MCAS (Figure 1). Psychological stress has pro-inflammatory effects via stimulation of mast cells, especially by CRH leading to increased vascular permeability. This process also leads to disruption of the blood-brain barrier (BBB), via release of IL-6 and CRH, further exacerbating brain inflammation by permitting the entry into the brain of more viral particles, cytokines, or other toxic substances (Table 1). A recent NIH study reported blood vessel damage and inflammation, but no infection, in brains of patients with COVID-19 (https://www.nih.gov/news-events/news-releases/nih-study-uncovers-blood-vessel-damage-inflammation-

**TABLE 2** Chemotherapeutic agents implicated in chemofog

| Chemotherapeutic agents | |
|-------------------------|--|
| Bleomycin               |
| Carboplatin             |
| Cis-platin              |
| Cyclophosphamide        |
| Cytarabine              |
| Doxetaxel               |
| Doxorubicin             |
| Lenalidomide            |
| Methotrexate            |
| Taxol                   |
| Trastuzumab             |

Note: The drugs listed, especially those bolded, have been reported to induce “chemofog” or “chemobrain”.

**FIGURE 1** Diagrammatic representation of how SARS-CoV-2 could stimulate mast cells and microglia in the hypothalamus, inhibited by luteolin. SARS-CoV-2 could enter the brain via the olfactory nerve tract reaching the hypothalamus where it could activate brain mast cells and microglia to release pro-inflammatory molecules, thus contributing to brain inflammation and brain fog. The effect of SARS-CoV-2 could be exaggerated by chemotherapy, as well as cytokines and mtDNA, or neuropeptides released under stress (thunderbolt). These processed could contribute to the pathogenesis and symptoms of long-COVID syndrome and “chemobrain” and could be prevented by the flavonoid luteolin.
SARS-CoV-2 could lead to release of pro-inflammatory mediators such as histamine, tryptase, and cytokines (IL-6, IL-1β, and tumor necrosis factor [TNF]) especially when primed by IL-33. Histamine can stimulate macrophages to release IL-1, which stimulates mast cells to release IL-6. Mast cells can also secrete mitochondrial DNA (mtDNA), which was recently reported to be increased in the serum of COVID-19 patients and correlated with disease severity. Extra-cellular mtDNA serves as an alarmin and stimulates pro-inflammatory mediator secretion from immune cells. Moreover, mast cells synthesize and release platelet activating factor (PAF), which has been implicated in the inflammation and microthromboses characterizing COVID-19.

**4 | Treatment Approaches**

Unfortunately, there are no clinically effective interventions for long-COVID syndrome or brain fog associated with either chemobrain, ME/CFS, or MCAS. It is also hard to decide whether it would be best to stimulate or suppress the immune system, since antibody production and T cells appear to be protective, while pro-inflammatory cytokines are destructive. A reasonable approach especially for brain fog associated with long-COVID syndrome, ME/CFS, MCAS, and chemotherapy-induced “chemobrain” would be inhibition of mast cell-associated neuroinflammation.

Even though inhibition of mast cells could be beneficial in COVID-19 or long-COVID syndrome, there are no effective mast cell inhibitors. Instead, mast cells could be inhibited with the structurally related natural flavonoids luteolin and quercetin, which are readily available and are generally considered safe. Figure 1). Both flavonoids have broad anti-viral properties, inhibit entry of the virus into host cells, and inhibit neuroinflammation, and reduce cognitive decline. Furthermore, luteolin better penetrates into the brain, inhibits both microglia and mast cells, and has been reported to reduce neuroinflammation and cognitive dysfunction, including Alzheimer’s disease in humans and in animal models.

Luteolin and quercetin are difficult to absorb after oral administration, but their pharmacokinetics are greatly improved in liposomal preparations using olive pomace oil. In fact, a luteolin formulation in olive pomace oil (NeuroProtek®) has been used effectively for improving autism spectrum disorder, while another one (BrainGain®) reduced brain fog. These liposomal formulations not only improve oral absorption and bioavailability but also provide the additional neuro-protective and anti-inflammatory actions of flavonoids.

**Table 3** Important facts and outstanding issues concerning long-COVID syndrome

| Issue | Action |
|-------|--------|
| Long-COVID syndrome is a serious concern |  |
| Symptoms of long-COVID syndrome are similar to those present in ME/CFS, MCAS and during or after chemotherapy |  |
| The most vexing symptoms are chronic physical and mental fatigue (brain fog) |  |
| The mechanism underlying these symptoms is presently not known |  |
| Stress-related neuropeptides and interferons could induce ACE2 expression on mast cells and microglia |  |
| Stimulation of hypothalamic mast cells and microglia by SARS-CoV-2 could lead to release of pro-inflammatory mediators |  |
| Focal inflammation of the brain may be prevented/reduced by appropriate liposomal luteolin formulations |  |

Abbreviations: ACE2, angiotensin converting enzyme 2; MCAS, mast cell activation syndrome; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.
olive pomace oil polyphenols, as well as the increase in memory provided by the olive hydroxytyrosol present in BrainGain®.

However, one should be aware of the fact that luteolin is now present in numerous dietary supplements with misleading names (e.g., “luteolin complex”) and wide variations in the source, content, and purity (often not disclosed at all) of luteolin.163

5 | CONCLUSION
The number of COVID-19 cases may turn out to be fewer and the associated burden to the health system more by the long-COVID syndrome.174 Obviously, there are many outstanding issues to be investigated (Table 3). In the meantime, the brain fog associated with long-COVID syndrome and use of chemotherapy may be prevented/reduced with appropriate luteolin formulations.

ACKNOWLEDGMENTS
This work was supported by anonymous donations.

AUTHOR CONTRIBUTIONS
Theoharis C. Theoharides conceived the concept, critically reviewed the literature and wrote the manuscript. Christos Cholevas and Konstantinos Polyzoidis assisted with the review of the literature.

CONFLICT OF INTEREST
Theoharis C. Theoharides is the Scientific Director of and shareholder in Algonot, LLC (Sarasota, FL), which develops and markets flavonoid-containing dietary supplements. He is also the recipient of US Patent No. 8,268,365, “Anti-inflammatory compositions for treating brain inflammation.” The other authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
No data.

ORCID
Theoharis C. Theoharides © https://orcid.org/0000-0002-1598-460X

REFERENCES
1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–13.
2. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.
3. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327–31.
4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglu K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000.
5. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.
6. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69(3):379–88.
7. Ragab D, Salah EH, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
8. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–36.
9. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.
10. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694–703.
11. Liu F, Li L, Xu M, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
12. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146(3):518–34.
13. Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, et al. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971–5.
14. Levin M. Childhood multisystem inflammatory syndrome - a new challenge in the pandemic. N Engl J Med. 2020;383(4):393–5.
15. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.
16. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453–4.
17. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–88.
18. Consiglio CR, Cotugno N, Sardh F, Pou C, Amadio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968–81.
19. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4.
20. Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146(5):949–59.
21. Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. 2020. https://doi.org/10.1002/jmv.26624.

22. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–70.

23. Foutihi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3–19.

24. Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020;17(1):231.

25. Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatol Ther. 2020;33(4):e13591.

26. Ongur D, Perlis R, Goff D. Psychiatry and COVID-19. JAMA. 2020;324(12):1149–50.

27. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531–42.

28. Pfefferbaum B, North CS. Mental health and the Covid-19 outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228–9.

29. Gordon JA, Borja SE. The COVID-19 pandemic: setting the mental Health Research agenda. Biol Psychiatry. 2020;88(2):130–1.

30. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Awasthi R. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15(11):e0240784.

31. Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it Mast cell activation syndrome. J Biol Regul Homeost Agents. 2020;34(5):1633–6.

32. Theoharides TC, Valent P, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115(2):216–23.

33. Hatzigelaki E, Adamaki M, Tsilioni I, Dimitriadis G, Rodiou A, Peri T, et al. Chemotherapy-related cognitive impairment or ‘chemo-fog’: concept and state of art. Geriatr Psyc Res. 2017;5:1–9.

34. Mitchell T, Turton P. ‘Chemobrain’: concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study. Eur J Cancer Care (Engl). 2016;25(1):66–71.

35. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099–104.

36. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639–56.

37. Theoharides TC, Valent P, Mast Cells AC. Mastocytosis and related disorders. N Engl J Med. 2015;373(2):163–72.

38. Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020;14(5):259–61.

39. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128:344–50.

40. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115(2):216–23.

41. Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2015;30(1):124–30.

42. Desai A, Jung MY, Olivera A, Gillifran AM, Prussin C, Kirschbaum AS, et al. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016;137(6):1863–71.

43. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. https://doi.org/10.1016/S1470-2045(20)30096-6.

44. Cascella M, Di NR, Carbone D, Cuomo GF, Bimonte S, Muzzio MR. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives. Recenti Prog Med. 2018;109(11):523–30.

45. Lange M, Joly F. How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract. 2017;13(12):784–90.

46. Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Mathew SS, et al. Is ‘chemo-fog’/’chemo-brain’ caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31(2):129–38.

47. Raffa RB. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’). J Clin Pharm Ther. 2011;36(3):257–9.

48. Mitchell T, Turton P. ‘Chemobrain’: concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study. Eur J Cancer Care (Engl). 2011;20(4):339–48.

49. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS ONE. 2014;9(9):e108002.

50. Chemobrain BW. An opportunity in cancer survivorship to enhance patient wellness. J Oncol Pract. 2017;13(12):794–6.

51. Bompaire F, Durand T, Leger-Hardy I, Psimaras D, Ricard D. Chemotherapy-related cognitive impairment or <<chemobrain>>: concept and state of art. Geriatr Psychiat Neuropsyhiat Vieil. 2017;15(1):89–98.

52. Subramanian SV, Mejia-Guevara I, Krishna A. Rethinking policy perspectives on childhood stunting: time to formulate a structural and multifactorial strategy. Matern Child Nutr. 2016;12(Suppl 1):219–36.

53. Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Mathew SS, et al. Is ‘chemo-fog’/’chemo-brain’ caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31(2):129–38.

54. Raffa RB. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’). J Clin Pharm Ther. 2011;36(3):257–9.

55. Mitchell T, Turton P. ‘Chemobrain’: concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study. Eur J Cancer Care (Engl). 2011;20(4):339–48.

56. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS ONE. 2014;9(9):e108002.

57. Chemobrain BW. An opportunity in cancer survivorship to enhance patient wellness. J Oncol Pract. 2017;13(12):794–6.

58. Gutmann DH. Clearing the fog surrounding Chemobrain. Cell. 2019;176(1–2):2–4.

59. Henderson FM, Cross AJ, Baraniak AR. A new normal with chemobrain: experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors. Health Psychol Open. 2019;6(1):2055102919832234.
55. Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.

56. Scherling CS, Smith A. Opening up the window into “chemobrain”: a neuroimaging review. Sensors (Basel). 2013;13(3):3169–203.

57. Eide S, Feng ZP. Doxorubicin chemotherapy-induced “chemo-brain”: meta-analysis. Eur J Pharmacol. 2020;881:173078.

58. El-Agamy SE, Bdel-Aziz AK, Esmat A, Azab SS. Chemotherapy-induced cognitive impairment. Cytokine. 2015;72(1):86–97.

59. Leake I. Aberrant adaptive myelination in chemobrain: a neuroimaging review. Sensors (Basel). 2013;13(3):3169–203.

60. Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol. 2020;324:113118.

61. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130(1–2):166–76.

62. Raffa RB. Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). J Clin Pharm Ther. 2013;38(4):265–8.
blood-brain barrier, neuroinflammation and Alzheimer’s disease. Front Cell Neurosci. 2019;13:54.
91. Hanssen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217(2):459–72.
92. Zhang X, Dong H, Li N, Zhang S, Sun J, Zhang S, et al. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis. J Neuroinflammation. 2016;13(1):127.
93. Moura DS, Sultan S, Georgin-Lavialle S, Barete S, Lortholary O, Gaillard R, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS ONE. 2012;7(6):e39468.
94. Afrin LB, Pohlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, et al. Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun. 2015;50:314–21.
95. Theoharides TC. Effect of stress on neuroimmune processes. Clin Ther. 2020;42:1007–14.
96. Theoharides TC, Donelan JM, Papadopoulo N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.
97. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci. 2007;12:1615–28.
98. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7:49.
99. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690–4.
100. Kempuraj D, Papadopoulo NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145:43–8.
101. Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 2020;384(5):481–3. https://doi.org/10.1056/NEJMc2033369.
102. Nazari S, Azari JA, Mirmoeeni S, Sadeghian S, Heidari ME, Sadeghian S, et al. Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis. Brain Behav. 2021:e02025. https://doi.org/10.1002/brb3.2025.
103. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130–40.
104. Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24):4017–20.
105. Olivera A, Beaver MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol. 2018;142(2):381–93.
106. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54.
107. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999;849:1–15.
108. Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241.
109. Theoharides TC. Potential association of mast cells with COVID-19. Ann Allergy Asthma Immunol. 2020;126(3):217–8.
110. Motta Junior JDS, Miggliolaro AFRD, Nagashima S, de Paula CBV, Baena CP, Scharfstein J, et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to Immunothrombosis. Front Immunol. 2020;11:574862.
111. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.
112. Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sinisanopoulos N, Yang H, et al. Neureotensin and CRH interactions augment human mast cell activation. PLoS One. 2012;7(11):e48934.
113. Asadi S, Alysandratos KD, Angelidou A, Mioni A, Sinisanopoulos N, Vasiadi M, et al. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol. 2012;132(2):324–9.
114. Taracanova A, Alevizos M, Karakouni A, Wenz G, Norwitz E, Conti P, et al. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci U S A. 2017;114(20):E4002–9.
115. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tsouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial Cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–35.
116. Dietrich N, Rohde M, Geffers R, Kroger A, Hauser H, Weiss S, et al. Mast cells elicit proinflammatory but not type 1 interferon responses upon activation of TLRs by bacteria. Proc Natl Acad Sci U S A. 2010;107(19):8748–53.
117. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121–50.
118. Bavazer MA, Theoharides TC. IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-kappaB, inhibited by methoxyluteolin. Eur J Pharmacol. 2019;865:172760.
119. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol. 2003;171(9):4830–6.
120. Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A. 2018;115(40):E9381–90.
121. Saluja R, Khan M, Church MK, Maurer M. The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy. 2015;5:33.
122. Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. J Allergy Clin Immunol. 2019;143:451.
123. Conti P, Caraffa A, Tete G, Gallenga CE, Ross R, Kritas SK, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. 2020;34(5):1629–32.

124. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One. 2012;7(12):e49767.

125. Scozzi D, Cano M, Ma L, Zhou D, Zhu JH, O’Halloran JA, et al. Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19. JCI Insight. 2021;6(4):e143299.

126. Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol. 2004;75(6):995–1000.

127. Sun S, Sursal T, Adibnia Y, Zhao C, Zheng Y, Li H, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One. 2013;8(3):e59989.

128. Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation and platelet activating factor. Biofactors. 2020;46(6):927–33.

129. Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;42(10):1850–2.

130. Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;42(10):1850–2.

131. Richman S, Morris MC, Broderick G, Craddock TJA, Klimas NG, Fletcher MA. Pharmaceutical interventions in chronic fatigue syndrome: a literature-based commentary. Clin Ther. 2019;41(5):798–805.

132. Jamiloux Y, Henry T, Belot A, Viel S, Fauter M, el Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.

133. Ronconi G, Tete G, Kritas SK, Gallenga CE, Al Caraffa RR, Conti P. SARS-CoV-2, which induces COVID-19, causes Kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents. 2020;34(3):767–73.

134. Gomez-Lopez N, StLouis D, Lehr MA, Sanchez-Rodriguez EN, Renas-Hernandez M. Immune cells in term and preterm labor. Cell Mol Immunol. 2014;11(6):571–81.

135. Theoharides TC, Conti P. Dexamethasone for COVID-19? not so fast. J Biol Regul Homeost Agents. 2020;34(3):1241–3.

136. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020;46(3):306–8.

137. Kempturaj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol. 2005;145:934–44.

138. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med. 2008;74(14):1667–77.

139. Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonoles/flavonoids in neurodegeneration and neuroinflammation. Mini Rev Med Chem. 2020;20(15):1475–88.

140. Jager AK, Saaby L. Flavonoids and the CNS. Molecules. 2011;16(2):1471–85.

141. Leyva-Lopez N, Gutierrez-Grijalva EP, Mbriz-Perez DL, Heredia JB. Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. Int J Mol Sci. 2016;17(6):921. https://doi.org/10.3390/ijms17060921.

142. Harwood M, Nielew ska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45(11):2179–205.

143. Okamoto T. Safety of quercetin for clinical application (review). Int J Mol Med. 2005;16(2):275–8.

144. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592–602.

145. Theoharides TC, Conti P, Economu M. Brain inflammation, neuropsychiatric disorders, and immunoenocrine effects of luteolin. J Clin Psychopharmacol. 2014;34(2):187–9.

146. Andres S, Pevny S, Ziegenhagen R, Bakhiya N, Schäfer B, Hirsch-Ernst KI, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018;62(1). https://doi.org/10.1002/mnfr.201700447.

147. Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL.Roles of flavonoids against coronavirus infection. Chem Biol Interact. 2020;328:109211.

148. Derosa G, Maffioli P, D’Angelo A, Di PF. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 2021;35(3):1230–6. https://doi.org/10.1002/ptr.6887.

149. Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation. Mini Rev Med Chem. 2020;20(15):1475–88.

150. Devi SA, Chamoli A. Polyphenols as an effective therapeutic intervention against cognitive decline during normal and pathological brain aging. Adv Exp Med Biol. 2020;1260:159–74.

151. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A. 2008;105(21):7534–9.

152. Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016;113:E7049–58.

153. Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol. 2020;153(4):1044–52.

154. Patel AB, Theoharides TC. Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J Pharmacol Exp Ther. 2017;361(3):462–71.

155. Ashaari Z, Hadjizadeh MA, Hassanzadeh G, Alizamir T, Yousefi B, Keshavarzi Z, et al. The flavone Luteolin improves central nervous system disorders by different mechanisms: a review. J Mol Neurosci. 2018;65(4):491–506.
Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Biofactors. 2020. https://doi.org/10.1002/biof.1687.

Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain “fog,” inflammation and obesity: key aspects of 2 neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015; 9:225.

Rezai-Zadeh K, Douglas SR, Bai Y, Tian J, Hou H, Mori T, et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer’s disease beta-amyloid production. J Cell Mol Med. 2009;13(3):574–88.

Kwon Y. Luteolin as a potential preventive and therapeutic candidate for Alzheimer’s disease. Exp Gerontol. 2017;95:39–43.

Delgado A, Cholevas C, Theoharides TC. Neuroinflammation in Alzheimer’s disease and beneficial action of luteolin. Biofactors. 2021. https://doi.org/10.1002/biof.1714.

Wang H, Wang H, Cheng H, Che Z. Ameliorating effect of luteolin on memory impairment in an Alzheimer’s disease model. Mol Med Rep. 2016;13(5):4215–20.

Fu X, Zhang J, Guo L, Xu Y, Sun L, Wang S, et al. Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav. 2014;126:122–30.

Theoharides TC. Luteolin supplements: all that glitters is not gold. Biofactors. 2020. https://doi.org/10.1002/biof.1689.

Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism Spectrum disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry. 2015;5:e647.

Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature. 2005;437(7055):45–6.

Angeloni C, Malaguti M, Barbalace MC, Hrelia S. Bioactivity of olive oil phenols in neuroprotection. Int J Mol Sci. 2017; 18(11):2230. https://doi.org/10.3390/ijms18112230.

Casamenti F, Stefani M. Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. Expert Rev Neurother. 2017;17(4):345–58.

Omar SH, Scott CJ, Hamlin AS, Obied HK. Olive biophenols reduces Alzheimer’s pathology in SH-SY5Y cells and APPswe mice. Int J Mol Sci. 2018;20(1):125. https://doi.org/10.3390/ijms20010125.

Calahorra J, Shenk J, Wielenga VH, Verweij V, Geenen B, Dederen PJ, et al. Hydroxytyrosol, the major phenolic compound of olive oil, as an acute therapeutic strategy after ischemic stroke. Nutrients. 2019;11(10):2430. https://doi.org/10.3390/nu11102430.

Khalatbary AR. Olive oil phenols and neuroprotection. Nutr Neurosci. 2013;16(6):243–9.

Marquez-Martín A, de La PR, Fernandez-Arche A, Ruiz-Gutierrez V, Yaqoob P. Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells. Cytokine. 2006;36(5–6):211–7.

Hornedo-Ortega R, Cerezo AB, de Pablos RM, Krisa S, Richard T, García-Parrilla MC, et al. Phenolic compounds characteristic of the Mediterranean diet in mitigating microglia-mediated neuroinflammation. Front Cell Neurosci. 2018;12:373.

Bertelli M, Kiani AK, Paolacci S, Manara E, Kurti D, Dhuli K, et al. Hydroxytyrosol: a natural compound with promising pharmacological activities. J Biotechnol. 2020;309:29–33.

The Lancet PH. Post-COVID-19 spending. Lancet Planet Health. 2020;4(5):e168.

How to cite this article: Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. BioFactors. 2021;47:232–241. https://doi.org/10.1002/biof.1726